Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 512
- Registration Number
- NCT03430843
- Locations
- 🇧🇪
UZ Antwerpen, Antwerp, Belgium
🇨🇳Anhui Medical University - The Second Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
Anlotinib and Irinotecan for Ewing Sarcoma
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT03416517
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 65
- Registration Number
- NCT03403101
- Locations
- 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
🇨🇳Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai, China
Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Peking University
- Target Recruit Count
- 55
- Registration Number
- NCT03400592
- Locations
- 🇨🇳
Peking cancer hospital, Beijing, Beijing, China
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas
- Conditions
- Interventions
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2021-02-26
- Target Recruit Count
- 112
- Registration Number
- NCT03387592
- Locations
- 🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy
🇮🇹Azienda Ospedaliera-Universitaria di Modena, Modena, MO, Italy
🇮🇹Ospedale Civile degli Infermi, Faenza, RA, Italy
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2021-09-02
- Target Recruit Count
- 120
- Registration Number
- NCT03387904
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Fujian Cancer Hospital
- Registration Number
- NCT03380689
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
- Conditions
- Interventions
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 116
- Registration Number
- NCT03374254
- Locations
- 🇺🇸
Seattle Cancer Care Alliance ( Site 0104), Seattle, Washington, United States
🇺🇸Rutgers Cancer Institute of New Jersey ( Site 0107), New Brunswick, New Jersey, United States
🇨🇦Princess Margaret Cancer Centre ( Site 0122), Toronto, Ontario, Canada
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 70
- Registration Number
- NCT03368859
- Locations
- 🇺🇸
USC Norris Cancer Center /ID# 200410, Los Angeles, California, United States
🇺🇸University of California, Los /ID# 169294, Santa Monica, California, United States
🇺🇸Florida Cancer Specialist - South /ID# 203796, Fort Myers, Florida, United States
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
- Conditions
- Interventions
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT03366155
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.